Angle gains on breakthrough in cancer diagnostic technology

Angle advanced more than 90 per cent Monday after the medtech company announced a major breakthrough in its cancer diagnostic product Parsotix.

Angle advanced more than 90 per cent Monday after the medtech company announced a major breakthrough in its cancer diagnostic product Parsotix.

The AIM listed company said it had edged further in the development of Parsortix, a non-invasive technology which captures and counts rare circulating tumour cells (CTC) from the blood of cancer patients.

Angle has designed a process for recovering the captured calls from the Parsotix cassette. The cells are then analysed by a variety of contemporary molecular techniques.

CTC analysis, through the use of such techniques, extends the Parsortix technology's capability and opens up new diagnostic, prognostic and treatment applications for cancer patients.

Angle expects its market to grow as it is the first device designed to recover CTCs. Analysis of CTCs can be used to screen and diagnose patients.

The company said the technology monitors patients' response to treatment in a non-invasive manner without having to perform a tumour biopsy.

Angle's research partner, the Paterson Institute for Cancer Research, will be researching the potential for the Parsortix system.

Angle's Founder and Chief Executive, Andrew Newland, said: "This major development means that our system now offers two approaches to analysis of CTCs: counting and identification of cells captured within the cassette; and molecular analysis of cells recovered from the cassette as a liquid biopsy.

"We know from discussions with researchers and physicians that there is market demand for this versatility."

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
Prepare for the end of the epic bubble in US stocks
US stockmarkets

Prepare for the end of the epic bubble in US stocks

US stocks are as expensive as they’ve ever been. How can you prepare your portfolio for a bubble bursting?
18 Jan 2021
It's not just the UK – we're seeing pandemic housing booms across the globe
Property

It's not just the UK – we're seeing pandemic housing booms across the globe

Soaring house prices aren’t just a UK thing, they’re a worldwide phenomenon. And it’s no coincidence – the underlying cause is much the same. John Ste…
18 Jan 2021